Mechanisms of resistance to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors (‘targeted therapies’) largely...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236/
https://www.ncbi.nlm.nih.gov/pubmed/29319049
http://dx.doi.org/10.1038/bjc.2017.434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236/
https://www.ncbi.nlm.nih.gov/pubmed/29319049
http://dx.doi.org/10.1038/bjc.2017.434

Ejemplares similares